Acumen Pharmaceuticals, Inc. Stock-Based Compensation
Acumen Pharmaceuticals, Inc. (ABOS) reported Stock-Based Compensation of $4.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.52M, a 1.04% increase year-over-year.
- Acumen Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.40M, a 3.15% decline year-over-year.
- Acumen Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.42M, a 3.24% increase year-over-year.
- Acumen Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.46M, a 5.26% increase year-over-year.
- Acumen Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $9.85M, a 2.25% increase from fiscal 2024.
- Acumen Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $9.63M, a 56.79% increase from fiscal 2023.
- Acumen Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $6.14M, a 100.75% increase from fiscal 2022.
- Acumen Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $3.06M, a 232.00% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $4.92M 10-Q · filed 2026-08-12 | $7.34M derived: sum of 3 quarters · filed 2026-08-12 | $9.80M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.40M 10-Q · filed 2026-05-12 | $4.82M derived: sum of 2 quarters · filed 2026-05-12 | $7.28M derived: sum of 3 quarters · filed 2026-05-12 | $9.77M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $4.88M derived: sum of 2 quarters · filed 2026-03-26 | $7.38M derived: sum of 3 quarters · filed 2026-08-12 | $9.85M 10-K · filed 2026-03-26 |
| 2025-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.96M derived: sum of 2 quarters · filed 2026-08-12 | $7.43M 10-Q · filed 2025-11-12 | $9.78M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $4.97M 10-Q · filed 2026-08-12 | $7.32M derived: sum of 3 quarters · filed 2026-08-12 | $9.65M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.47M 10-Q · filed 2026-05-12 | $4.82M derived: sum of 2 quarters · filed 2026-05-12 | $7.16M derived: sum of 3 quarters · filed 2026-05-12 | $9.63M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $4.68M derived: sum of 2 quarters · filed 2026-03-26 | $7.15M derived: sum of 3 quarters · filed 2026-03-26 | $9.63M 10-K · filed 2026-03-26 |
| 2024-09-30 | $2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.81M derived: sum of 2 quarters · filed 2025-11-12 | $7.29M 10-Q · filed 2025-11-12 | $8.93M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $4.95M 10-Q · filed 2025-08-12 | $6.59M derived: sum of 3 quarters · filed 2025-08-12 | $8.19M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.48M 10-Q · filed 2025-05-13 | $4.12M derived: sum of 2 quarters · filed 2025-05-13 | $5.72M derived: sum of 3 quarters · filed 2025-05-13 | $7.24M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $3.23M derived: sum of 2 quarters · filed 2025-03-27 | $4.75M derived: sum of 3 quarters · filed 2025-03-27 | $6.14M 10-K · filed 2025-03-27 |
| 2023-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.12M derived: sum of 2 quarters · filed 2024-11-12 | $4.51M 10-Q · filed 2024-11-12 | $5.40M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.91M 10-Q · filed 2024-08-13 | $3.80M derived: sum of 3 quarters · filed 2024-08-13 | $4.64M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.39M 10-Q · filed 2024-05-14 | $2.28M derived: sum of 2 quarters · filed 2024-05-14 | $3.12M derived: sum of 3 quarters · filed 2024-05-14 | $3.83M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $888.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $1.73M derived: sum of 2 quarters · filed 2024-03-26 | $2.44M derived: sum of 3 quarters · filed 2024-03-26 | $3.06M 10-K · filed 2024-03-26 |
| 2022-09-30 | $840.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.55M derived: sum of 2 quarters · filed 2023-11-13 | $2.17M 10-Q · filed 2023-11-13 | $2.54M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $715.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.33M 10-Q · filed 2023-08-08 | $1.70M derived: sum of 3 quarters · filed 2023-08-08 | $2.00M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $618.00K 10-Q · filed 2023-05-09 | $983.00K derived: sum of 2 quarters · filed 2023-05-09 | $1.29M derived: sum of 3 quarters · filed 2023-05-09 | $1.41M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $669.00K derived: sum of 2 quarters · filed 2023-03-27 | $796.00K derived: sum of 3 quarters · filed 2023-03-27 | $922.00K 10-K · filed 2023-03-27 |
| 2021-09-30 | $304.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $431.00K derived: sum of 2 quarters · filed 2022-11-14 | $557.00K 10-Q · filed 2022-11-14 | $595.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $127.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $253.00K 10-Q · filed 2022-08-15 | $291.00K derived: sum of 3 quarters · filed 2022-08-15 | $330.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $126.00K 10-Q · filed 2022-05-16 | $164.00K derived: sum of 2 quarters · filed 2022-05-16 | $203.00K derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $77.00K derived: sum of 2 quarters · filed 2022-03-28 | $154.00K 10-K · filed 2022-03-28 | |
| 2020-09-30 | $39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $116.00K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $77.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |